September 30 In the three quarters ended, 2010, Akorn recognized $1.9 million in revenue and around $2.0 million in altered EBITDA as a total result of its participation in the Akorn-Strides LLC joint venture. Raj Rai, Chief Executive Officer, commented, That is a positive result for Akorn as the arises from the sale provide us with immediate usage of capital to accelerate our infrastructure improvements, go after acquisitions and in-licensing of specific niche market pharmaceuticals, in addition to our balance sheet strengthen. We would like to thank our jv partner, Strides, for assisting build value in our joint venture which includes resulted in a mutually beneficial strategic outcome. .. Akorn-Strides jv enters purchase agreement with Pfizer for ANDAs Akorn, Inc.Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and regional communities to support and expand usage of reliable, affordable health care around the world. For a lot more than 150 years, Pfizer spent some time working to create a difference for all who depend on us., , the live, attenuated Listeria monocytogenes immunotherapy business, has received formal authorization from the Medicines Controller General India to conduct a Stage II medical trial of ADXS11-001, the Company’s flagship drug construct, among 110 women with advanced, metastatic cervical cancer that has progressed after treatment with cytotoxic therapy.